Evaluation of efficacy of propranolol on hemangioma and lymphangioma.

Evaluation of efficacy of propranolol on hemangioma and lymphangioma. - Evaluation of efficacy of propranolol on hemangioma and lymphangioma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004626

Enrollment

Registered

2010-12-01

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemangioma, lymphangioma

Interventions

propranolol therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. More than after birth 2 weeks. 2. Hemangioma or lymphangioma. 3. Informed consent. 4. The patient who has contraception.

Exclusion criteria

Exclusion criteria: 1. Severe heart disease. 2. Hypotension. 3. Woman who are pregnant or breast feeding, and woman of childbearing potential. 4. Patient who has drug allergy, and patient with the past of serious side effect by the propranolol drug. 5. Patient who was considered ineligible by the investigators.

Design outcomes

Primary

Measure	Time frame
A change of the lesion size.	—

Secondary

Measure	Time frame
A side effect by blood pressure, the blood sugar level.	—

Countries

Japan

Contacts

Public ContactMiyuki Kohno

Kanazawa Medical University Hospital Department of Pediatric Surgery

miyuki@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026